Pregenesys pre-eclampsia markers consensus meeting: What do we require from markers, risk assessment and model systems to tailor preventive strategies?

Placenta

Volumn 32, Issue SUPPL. 1, 2011, Pages

  Cetin, I ^a   Huppertz, B ^b   Burton, G ^c   Cuckle, H ^d,e   Gonen, R ^f   Lapaire, O ^g   Mandia, L ^a   Nicolaides, K ^h   Redman, C ⁱ   Soothill, P ^j   Spencer, K ^k   Thilaganathan, B ^l   Williams, D ^m   Meiri, H ⁿ  

^a UNIVERSITY OF MILAN   (Italy)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF LEEDS   (United Kingdom)

^f BNAI ZION MEDICAL CENTER   (Israel)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^j ST MICHAEL'S HOSPITAL   (United Kingdom)

^k KING GEORGE HOSPITAL   (United Kingdom)

^l ST GEORGE S HOSPITAL   (United Kingdom)

^m UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁿ Diagnostic Technologies Ltd   (Israel)

more..

Author keywords

Early diagnosis; Endothelial damage; Genomics and proteomics markers; IUGR; PAPP A; PIGF; Placenta; PP13; Preeclampsia; PTX3; Surveillance; Uterine Doppler

Indexed keywords

ANGIOGENIC FACTOR; PENTRAXIN 3; PLACENTA PROTEIN; PLACENTA PROTEIN 13; UNCLASSIFIED DRUG;

ARTICLE; CONSENSUS DEVELOPMENT; COST BENEFIT ANALYSIS; DISEASE MARKER; EARLY DIAGNOSIS; ENDOTHELIUM LESION; INFLAMMATION; MATERNAL WELFARE; PERINATAL PERIOD; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; RISK ASSESSMENT; TROPHOBLAST;

BIOLOGICAL MARKERS; CONSENSUS; CONSENSUS DEVELOPMENT CONFERENCES AS TOPIC; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DIAGNOSTIC TECHNIQUES, OBSTETRICAL AND GYNECOLOGICAL; EARLY DIAGNOSIS; FEMALE; HEALTH PLANNING GUIDELINES; HUMANS; MODELS, BIOLOGICAL; PRE-ECLAMPSIA; PREGNANCY; PREVENTIVE MEDICINE; RISK ASSESSMENT; TROPHOBLASTS;

EID: 79151475360     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2010.11.022     Document Type: Article

References (108)

1. ACOG Committee on Obstetric Practice ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, 2002. American College of Obstetricians and Gynecologists Int J Gynaecol Obstet 77 2002 67 75
2. World Health Organization Make every mother and child Count. World health report, 2005 2005 World Health Organization Geneva, Switzerland
3. L. Bellamy, J.P. Casas, A.D. Hingorani, and D.J. Williams Pre-eclampsia and risk of cardiovascular disease and cancer in later life: a systematic review and meta-analysis BMJ 335 2007 974 977
4. S.D. McDonald, A. Malinowski, Q. Zhou, S. Yusuf, and P.J. Devereaux Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses Am Heart J 156 2008 918 930
5. Report of the national high blood pressure education program working group on high blood pressure in pregnancy Am J Obstet Gynecol 183 2000 S1 S22
6. G.C.S. Smith, J.P. Pell, and D. Walsh Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births Lancet 357 2001 1213 1216
7. B.M. Sibai, A. El-Nazer, and A. Gonzalez-Ruiz Severe preeclampsia- eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis Am J Obstet Gynecol 155 1986 1011 1016
8. C.W. Redman, G.P. Sacks, and I.L. Sargent Preeclampsia: an excessive maternal inflammatory response to pregnancy Am J Obstet Gynecol 180 1999 499 506
9. B.J. Ballermann Contribution of the endothelium to the glomerular permselectivity barrier in health and disease Nephron Physiol 106 2007 19 25
10. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, and S. Mondal Excess placental soluble fms-like tyrosine kinase 1 (sFlt-1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
11. V. Eremina, M. Sood, J. Haigh, A. Nagy, G. Lajoie, and N. Ferrara Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases J Clin Invest 111 2003 707 716
12. E.B. Magnussen, L.J. Vatten, T.I. Lund-Nilsen, K.A. Salvesen, G. Davey Smith, and P.R. Romundstad Prepregnancy cardiovascular risk factors as predictors of pre-eclampsia: population based cohort study BMJ 335 2007 978
13. D.J. Williams Pregnancy - a stress test for life Curr Opin Obstet Gynecol 15 2003 465 471
14. P.W. Soothill, R. Ajayi, S. Campbell, J. Gibbs, R. Chandran, and D. Gibb Effect of a fetal surveillance unit on admission of antenatal patients to hospital BMJ 303 1991 269 271
15. J. Menzies, L.A. Magee, J. Li, Y.C. MacNab, R. Yin, and H. Stuart Preeclampsia integrated estimate of RiSk (PIERS) study group. Instituting surveillance guidelines and adverse outcomes in preeclampsia Obstet Gynecol 110 2007 121 127
16. M. Chandiramani, J.J.S. Waugh, and A.H. Shennan Management of hypertension and pre-eclampsia in pregnancy Trends Urol Gynaecol Sex Health 12 2007 23 28
17. M. Noori, A.E. Donald, A. Angelakopoulou, A.D. Hingorani, and D.J. Williams Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension Circulation 122 2010 478 487
18. R.A. Simpson, T.M. Mayhew, and P.R. Barnes From 13 weeks to term, the trophoblast of human placenta grows by the continuous recruitment of new proliferative units: a study of nuclear number using the disector Placenta 13 1992 501 512
19. P. Kaufmann, S. Black, and B. Huppertz Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia Biol Reprod 69 2003 1 7
20. G. Moser, M. Gauster, K. Orendi, A. Glasner, R. Theuerkauf, and B. Huppertz Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models Hum Reprod 25 2010 1127 1136
21. B. Huppertz Placental origins of preeclampsia: challenging the current hypothesis Hypertension 51 2008 970 975
22. Y. Gigure, M. Charland, E. Bujold, N. Bernard, S. Grenier, and F. Rousseau Combining biochemical and Ultrasonographic markers in predicting preeclampsia: a systematic review Clin Chem 56 2010 361 375
23. L.C. Kenny, D.I. Broadhurst, W. Dunn, M. Brown, R.A. North, and L. McCowan Screening for pregnancy endpoints consortium. Robust early pregnancy prediction of later preeclampsia using metabolomic biomarkers Hypertension 56 2010 741 749
24. E. Bujold, S. Roberge, Y. Lacasse, M. Bureau, F. Audibert, and S. Marcoux Prevention of preeclampsia and intrauterine growth restriction with aspirin started in early pregnancy. A meta-analysis Obstetrics Gynecol 116 2010 401 414
25. D.E. Clark, S.K. Smith, D. Licence, A.L. Evans, and D.S. Charnock-Jones Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation J Endocrinol 159 1998 459 467
26. B.R. Kamat, L.F. Brown, E.J. Manseau, D.R. Senger, and H.F. Dvorak Expression of vascular permeability factor/vascular endothelial growth factor by human granulosa and theca lutein cells. Role in corpus luteum development Am J Pathol 146 1995 157 165
27. R. Akolekar, E. Zaragoza, L.C. Poon, S. Pepes, and K.H. Nicolaides Maternal serum placental growth factor at 11 + 0 to 13 + 6 weeks of gestation in the prediction of pre-eclampsia Ultrasound Obstet Gynecol 32 2008 732 739
28. R.J. Levine, S.E. Maynard, C. Qian, K.H. Lim, L.J. England, and K.F. Yu Circulating angiogenic factors and the risk of preeclampsia N Engl J Med 350 2004 672 683
29. S. Verlohren, A. Galindo, D. Schlembach, H. Zeisler, I. Herraiz, and M.G. Moertl An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia Am J Obstet Gynecol 202 2010 161 e1-161.e11
30. C.J. Robinson, D.D. Johnson, E.Y. Chang, D.M. Armstrong, and W. Wang Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia Am J Obstet Gynecol 195 2006 255 259
31. A.K. Wikstrom, A. Larsson, U.J. Eriksson, P. Nash, S. Norden-Lindeberg, and M. Olovsson Placental growth factor and soluble FMS-like tyrosine kinase-1 in early-onset and late-onset preeclampsia Obstet Gynecol 109 2007 1368 1374
32. H. Stepan, T. Krämer, and R. Faber Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction J Clin Endocrinol Metab 92 2007 2831 2834
33. H. Bohn, W. Kraus, and W. Winckler Purification and characterization of two new soluble placental tissue proteins (PP13 and PP17) Oncodev Biol Med 4 1983 343 350
34. N.G. Than, R. Romero, M. Goodman, A. Weckle, J. Xing, and Z. Dong A primate subfamily of galectins expressed at the maternal-fetal interface that promote immune cell death Proc Natl Acad Sci U S A 106 2009 9731 9736
35. B. Huppertz, M. Sammar, I. Chefetz, P. Neumaier-Wagner, C. Bartz, and H. Meiri Longitudinal determination of serum placental protein 13 during development of preeclampsia Fetal Diagn Ther 24 2008 230 236
36. R. Gonen, R. Shahar, Y.I. Grimpel, I. Chefetz, M. Sammar, and H. Meiri Placental protein 13 as an early marker for pre-eclampsia: a prospective longitudinal study BJOG 115 2008 1465 1472
37. R. Romero, J.P. Kusanovic, N.G. Than, O. Erez, F. Gotsch, and J. Espinoza First-trimester maternal serum PP13 in the risk assessment for preeclampsia Am J Obstet Gynecol 199 2008 122 e1-122.e11
38. A. Khalil, N.J. Cowans, K. Spencer, S. Goichman, H. Meiri, and K. Harrington First trimester maternal serum placental protein 13 for the prediction of pre-eclampsia in women with a priori high risk Prenat Diagn 29 2009 781 789
39. A. Khalil, N.J. Cowans, K. Spencer, S. Goichman, Meiri, and K. Harrington First trimester markers for the prediction of preeclampsia in women with a-priori high risk Ultrasound Obstet Gynecol 35 2010 671 679
40. A. Sekizawa, Y. Purwosunu, S. Yoshimura, M. Nakamura, H. Shimizu, and T. Okai PP13 mRNA expression in trophoblasts from preeclamptic placentas Reprod Sci 16 2009 408 413
41. A. Boronkai, S. Bellyei, A. Szigeti, E. Pozsgaia, Z. Bognar, and B. Sumegi Potentiation of paclitaxel-induced apoptosis by galectin-13 overexpression via activation of Ask-1-p38-MAPkinase and JNK/SAPK pathways and suppression of Akt and ERK1/2 activation in human macrophage cells Eur J Cell Biol 88 2009 753 763
42. S. Gebhardt, N. Bruiners, and R. Hillermann A novel exonic variant (221delT) in the LGALS13 gene encoding placental protein 13 (PP13) is associated with preterm labour in a low risk population J Reprod Immunol 82 2009 166 173
43. L. Dugoff, J.C. Hobbins, F.D. Malone, T.F. Porter, D. Luthy, and C.H. Comstock First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial) Am J Obstet Gynecol 191 2004 1446 1451
44. D. Krantz, L. Goetzl, J.L. Simpson, E. Thom, J. Zachary, and T.W. Hallahan First Trimester Maternal Serum Biochemistry and Fetal Nuchal Translucency Screening (BUN) Study Group. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes Am J Obstet Gynecol 191 2004 1452 1458
45. K. Spencer, N.J. Cowans, K. Avgidou, F. Milina, and K.H. Nicolaides First trimester biochemical markers of aneuploidy and the predicition of small for gestational age fetuses Ultrasound Obstet Gynecol 31 2008 15 19
46. K. Spencer, N.J. Cowans, and K.H. Nicolaides Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia Prenat Diagn 28 2008 7 10
47. L.C. Poon, N. Maiz, C. Valencia, W. Plasencia, and K.H. Nicolaides First-trimester maternal serum pregnancy-associated plasma protein-A and pre-eclampsia Ultrasound Obstet Gynecol 33 2009 23 33
48. G. Schmorl Pathologisch-anatomische Untersuchungen über Puerperal-Eklampsie 1893 Verlag FCW Vogel Leipzig
49. O. Lapaire, W. Holzgreve, J.C. Oosterwijk, R. Brinkhaus, and D.W. Bianchi Georg Schmorl on trophoblasts in the maternal circulation Placenta 28 2007 1 5
50. B. Huppertz, and J.C. Kingdom Apoptosis in the trophoblast-role of apoptosis in placental morphogenesis J Soc Gynecol Investig 11 2004 353 362
51. B. Huppertz, H.G. Frank, J.C. Kingdom, F. Reister, and P. Kaufmann Villous cytotrophoblast regulation of the syncytial apoptotic cascade in the human placenta Histochem Cell Biol 110 1998 495 508
52. D.W. Bianchi, J.L. Simpson, L.G. Jackson, S. Elias, W. Holzgreve, and M.I. Evans Fetal gender and aneuploidy detection using fetal cells in maternal blood: analysis of NIFTY I data. National Institute of Child Health and Development Fetal Cell Isolation Study Prenat Diagn 22 2002 609 615
53. L. Jackson Fetal cells and DNA in maternal blood Prenat Diagn 10 2003 837 846
54. D.W. Bianchi, J.M. Williams, L.M. Sullivan, F.W. Hanson, K.W. Klinger, and A.P. Shuber PCR quantitation of fetal cells in maternal blood in normal and aneuploid pregnancies Am J Hum Genet 61 1997 822 829
55. Y.M. Lo, N. Corbetta, P.F. Chamberlain, V. Rai, I.L. Sargent, and C.W. Redman Presence of fetal DNA in maternal plasma and serum Lancet 350 1997 485 487
56. R.J. Levine, C. Qian, E.S. Leshane, K.F. Yu, L.J. England, and E.F. Schisterman Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia Am J Obstet Gynecol 190 2004 707 713
57. M.S. Alberry, D.G. Maddocks, M.A. Hadi, H. Metawi, L.P. Hunt, and S.A. Abdel-Fattah Quantification of cell free fetal DNA in maternal plasma in normal pregnancies and in pregnancies with placental dysfunction Am J Obstet Gynecol 200 2009 98 e1-6
58. S. Illanes, M. Parra, R. Serra, K. Pino, H. Figueroa-Diesel, and C. Romero Increased free fetal DNA levels in early pregnancy plasma of women who subsequently develop preeclampsia and intrauterine growth restriction Prenat Diagn 29 2009 1118 1122
59. K.C. Chan, C. Ding, A. Gerovassili, S.W. Yeung, R.W. Chiu, and T.N. Leung Hypermethylated RASSF1A in maternal plasma: a universal fetal DNA marker that improves the reliability of noninvasive prenatal diagnosis Clin Chem 52 2006 2211 2218
60. D.W. Tsui, K.C. Chan, S.S. Chim, L.W. Chan, T.Y. Leung, and T.K. Lau Quantitative aberrations of hypermethylated RASSF1A gene sequences in maternal plasma in pre-eclampsia Prenat Diagn 27 2007 1212 1218
61. C.H. Diesch, W. Holzgreve, S. Hahn, and X.Y. Zhong Comparison of activin A and cell-free fetal DNA levels in maternal plasma from patients at high risk for preeclampsia Prenat Diagn 26 2006 1267 1270
62. A.K. Gupta, W. Holzgreve, B. Huppertz, A. Malek, H. Schneider, and S. Hahn Detection of fetal DNA and RNA in placenta-derived syncytiotrophoblast microparticles generated in vitro Clin Chem 50 2004 2187 2190
63. E.K. Ng, T.N. Leung, N.B. Tsui, T.K. Lau, N.S. Panesar, and R.W. Chiu The concentration of circulating corticotropin-releasing hormone mRNA in maternal plasma is increased in preeclampsia Clin Chem 49 2003 727 731
64. X.Y. Zhong, S. Gebhardt, R. Hillermann, K.C. Tofa, W. Holzgreve, and S. Hahn Parallel assessment of circulatory fetal DNA and corticotropin-releasing hormone mRNA in early- and late-onset preeclampsia Clin Chem 51 2005 1730 1733
65. Y. Purwosunu, A. Sekizawa, A. Farina, N. Wibowo, S. Okazaki, and M. Nakamura Cell-free mRNA concentrations of CRH, PLAC1, and selectin-P are increased in the plasma of pregnant women with preeclampsia Prenat Diagn 27 2007 772 777
66. C. Garlanda, B. Bottazzi, A. Bastone, and A. Mantovani Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility Annu Rev Immunol 23 2005 337 366
67. S. Tranguch, A. Chakrabarty, Y. Guo, H. Wang, and S.K. Dey Maternal pentraxin 3 deficiency compromises implantation in mice Biol Reprod 77 2007 425 432
68. I. Cetin, V. Cozzi, F. Pasqualini, M. Nebuloni, C. Garlanda, and L. Vago Elevated maternal levels of the long pentraxin 3 (PTX3) in preeclampsia and intrauterine growth restriction Am J Obstet Gynecol 194 2006 1347 1353
69. P. Rovere-Querini, S. Antonacci, G. Dell'Antonio, A. Angeli, G. Almirante, and E.D. Cin Plasma and tissue expression of the long pentraxin 3 during normal pregnancy and preeclampsia Obstet Gynecol 108 2006 148 155
70. I. Cetin, V. Cozzi, A.T. Papageorghiou, V. Maina, A. Montanelli, and C. Garlanda First trimester PTX3 levels in women who subsequently develop preeclampsia and fetal growth restriction Acta Obst et Gyn 88 2009 846 849
71. R. Akolekar, D. Casagrandi, P. Livanos, A. Tetteh, and K.H. Nicolaides Maternal plasma pentraxin 3 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy Prenat Diagn 29 2009 934 938
72. L.C. Poon, R. Akolekar, R. Lachmann, J. Beta, and K.H. Nicolaides Hypertensive disorders in pregnancy: screening by biophysical and biochemical markers at 11-13 weeks Ultrasound Obstet Gynecol 35 2010 662 670
73. A.M. Martin, R. Bindra, P. Curcio, S. Cicero, and K.H. Nicolaides Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler at 11-14 weeks of gestation Ultrasound Obstet Gynecol 18 2002 583 586
74. K. Spencer, N.J. Cowans, I. Chefetz, J. Tal, and H. Meiri First-trimester maternal serum pp-13, papp-a and second-trimester uterine artery doppler pulsatility index as markers of pre-eclampsia Ultrasound Obstet Gynecol 29 2007 128 134
75. L.C. Poon, I. Staboulidou, N. Maiz, W. Plasencia, and K.H. Nicolaides Hypertensive disorders in pregnancy: screening by uterine artery Doppler at 11-13 weeks Ultrasound Obstet Gynecol 34 2009 142 148
76. Cuckle H. Screening for pre-eclampsia - lessons from aneuploidy screening Placenta supplement early non-invasive marker.
77. K. Melchiorre, B. Wormald, K. Leslie, A. Bhide, and B. Thilaganathan First-trimester uterine artery Doppler indices in term and preterm pre-eclampsia Ultrasound Obstet Gynecol 32 2008 133 137
78. F. Prefumo, N. Fratelli, R. Ganapathy, A. Bhide, T. Frusca, and B. Thilaganathan First trimester uterine artery Doppler in women with previous pre-eclampsia Acta Obstet Gynecol Scand 87 2008 1271 1275
79. P. Dar, J. Gebb, L. Reimers, P.S. Bernstein, C. Chazotte, and I.R. Merkatz First-trimester 3-dimensional power Doppler of the uteroplacental circulation space: a potential screening method for preeclampsia Am J Obstet Gynecol 203 2010 238 e1-7
80. L.C. Poon, N.A. Kametas, I. Pandeva, C. Valencia, and K.H. Noclaides Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of pre-eclampsia Hypertension 51 2008 1027 1033
81. J.G. Ray, M.J. Vermeulen, M.J. Schull, and D.A. Redelmeier Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study Lancet 366 2005 1797 1803
82. P.R. Romundstad, E.B. Magnussen, G. Davey Smith, and L.J. Vatten Hypertension in pregnancy and later cardiovascular risk. Common antecedents? Circulation 122 2010 579 584
83. R.J. Levine, L.J. Vatten, G.L. Horowitz, C. Qian, P.R. Romundstad, and K.F. Yu Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study BMJ 339 2009 b4336
84. D. Gordin, V. Hiilesmaa, J. Fagerudd, M. Rönnback, C. Forsblom, and R. Kaaja Pre-eclampsia but not pregnancy-induced hypertension is a risk factor for diabetic nephropathy in type 1 diabetic women Diabetologia 50 2007 516 522
85. N.J. Cowans, A. Stamatopoulou, J. Hellstrom, M.-M. Makela, and K. Spencer PAPP-A and free β-hCG stability in first trimester serum using PerkinElmer AutoDELFIA and DELFIA Xpress Prenat Diagn 30 2010 127 132
86. N.J. Cowans, A. Stamatopoulou, S. Jaakohuhta, and K. Spencer ADAM-12 stability in first trimester maternal serum Prenat Diagn 30 2010 555 560
87. N.J. Cowans, A. Stamatopoulou, S. Jaakohuhta, S. Hentunen, and K. Spencer PP13 stability in first trimester maternal serum and whole blood Prenat Diagn 30 2010 582 585
88. J.S. Cnossen, G. ter Riet, B.W. Mol, J.A. van der Post, M.M. Leeflang, and C.A. Meads Are tests for predicting pre-eclampsia good enough to make screening viable? A review of reviews and critical appraisal Acta Obst Gyn 88 2009 758 765
89. K. Spencer, C.E. Spencer, M. Power, A. Moakes, and K.H. Nicolaides One stop clinic for assessement of risk (OSCAR) for fetal anomalies: a report of the first year of prospecive screening for chromosomal anomalies in the first trimester BJOG 107 2000 1271 1275
90. V.L. Bills, J. Varet, A. Millar, S.J. Harper, P.W. Soothill, and D.O. Bates Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia Clin Sci (Lond) 116 2009 Feb 265 272 Erratum in: Clin Sci (Lond) 2009;116:873
91. R. Akolekar, D. Casagrandi, E. Skyfta, A.A. Ahmed, and K.H. Nicolaides Maternal serum angiopoietin-2 at 11 to 13 weeks of gestation in hypertensive disorders of pregnancy Prenat Diagn 29 2009 847 851
92. R. Akolekar, R. Minekawa, A. Veduta, X.C. Romero, and K.H. Nicolaides Maternal plasma inhibin A at 11-13 weeks of gestation in hypertensive disorders of pregnancy Prenat Diagn 29 2009 753 760
93. R. Akolekar, A. Syngelaki, J. Beta, R. Kocylowski, and K.H. Nicolaides Maternal serum placental protein 13 at 11-13 weeks of gestation in preeclampsia Prenat Diagn 29 2009 1103 1108
94. R. Akolekar, A. Etchegaray, Y. Zhou, N. Maiz, and K.H. Nicolaides Maternal serum activin at 11-13 weeks of gestation in hypertensive disorders of pregnancy Fetal Diagn Ther 25 2009 320 327
95. A.M. Leal, L.C. Poon, V. Frisova, A. Veduta, and K.H. Nicolaides First-trimester maternal serum tumor necrosis factor receptor-1 and pre-eclampsia Ultrasound Obstet Gynecol 33 2009 135 141
96. L.C. Poon, E. Nekrasova, P. Anastassopoulos, P. Livanos, and K.H. Nicolaides First-trimester maternal serum matrix metalloproteinase-9 (MMP-9) and adverse pregnancy outcome Prenat Diagn 29 2009 553 559
97. L.C. Poon, T. Chelemen, R. Minekawa, V. Frisova, and K.H. Nicolaides Maternal serum ADAM12 (A disintegrin and metalloprotease) in chromosomally abnormal pregnancy at 11-13 weeks Am J Obstet Gynecol 200 2009 508 e1-6
98. M. Savvidou, R. Akolekar, E. Zaragoza, L. Poon, and K. Nicolaides First trimester urinary placental growth factor and development of pre-eclampsia BJOG 116 2009 643 647
99. S. Sifakis, A. Zaravinos, N. Maiz, D.A. Spandidos, and K.H. Nicolaides First-trimester maternal plasma cell-free fetal DNA and preeclampsia Am J Obstet Gynecol 201 2009 472 e1-7
100. I. Staboulidou, A. Galindo, N. Maiz, G. Karagiannis, and K.H. Nicolaides First-trimester uterine artery Doppler and serum pregnancy-associated plasma protein-a in preeclampsia and chromosomal defects Fetal Diagn Ther 25 2009 336 339
101. H. Cuckle, and P. Benn Multianalyte. Maternal serum screening for chromosomal defects A. Milunsky, J.M. Milunsky, Genetic disorders and the fetus: diagnosis, prevention and treatment - 6th edition 2010 Johns Hopkins University Press Baltimore 771 818
102. L.C. Poon, N.A. Kametas, N. Maiz, R. Akolekar, and K.H. Nicolaides First-trimester prediction of hypertensive disorders in pregnancy Hypertension 53 2009 812 818
103. J.M.G. Wilson, and G. Jungner Principles and practice of screening for disease Public health Papers no. 43 vol. 22 1968 World Health Organisation Geneva (11):1-163
104. I. Cetin The use of LMWH in pregnancies at risk: new evidence or perception? J Thromb Haemost 3 2005 791 792
105. S.W. Wen, X.K. Chen, M. Rodger, R.R. White, Q. Yang, and G.N. Smith Folic acid supplementation in early second trimester and the risk of preeclampsia Am J Obstet Gynecol 198 2008 45 e1-7
106. G.J. Hofmeyr, T.A. Lawrie, Á.N. Atallah, and L. Duley Calcium supplementation during pregnancy Cochrane Database Syst Rev 8 2010 CD001059
107. L.C. Poon, N.A. Kametas, T. Chelemen, A. Leal, and K.H. Nicolaides Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach J Hum Hypertens 24 2010 104 110
108. R. Akolekar, A. Veduta, R. Minekawa, T. Chelemen, and K.H. Nicolaides Maternal plasma P- selectin at 11 to 13 Weeks of gestation in hypertensive disorders of pregnancy Hypertens Pregnancy 2010 [Epub ahead of print]